Hepatitis B vaccine recombinant - VBI Vaccines

Drug Profile

Hepatitis B vaccine recombinant - VBI Vaccines

Alternative Names: Bio-Hep-B; Hepimmune; Sci-B-Vac

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Weizmann Institute of Science
  • Developer VBI Vaccines
  • Class Hepatitis B vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 30 Aug 2017 US FDA accepts IND for Hepatitis B vaccine for phase III trial for review
  • 11 Jul 2017 VBI Vaccines plans phase III PROTECT and CONSTANT trials for Hepatitis B is USA, Canada and Europe in the second half of 2017
  • 19 Jun 2017 VBI Vaccines plans to file an IND application with the FDA in USA for Hepatitis B in second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top